A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

202

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

October 22, 2027

Study Completion Date

April 22, 2028

Conditions

Advanced CancerAdvanced Solid Tumors

Interventions

DRUG

ALK201

Administered intravenously, once every 3 weeks

Trial Locations (1)

RECRUITING

Cancer Care Wollongong, Wollongong

All Listed Sponsors

lead

Shanghai Allink Biotherapeutics Co., Ltd.

INDUSTRY